Total Utang marang Modal Fate Therapeutics Corp (FATE)

Fate Therapeutics - logo grafis emiten FATE

Fate Therapeutics, Inc. (FATE) revenues rely on payments from pharmaceutical corporations for access to iPSC technologies while the results of its own research are pending. Effective management ensures reporting transparency and maintains the trust of major funds. Current price action regarding the total debt-to-equity ratio is 0.49. Fate Therapeutics, Inc. (FATE) holds a leading position in the development of stem cell-based oncology drugs, owning critical industry patents.

fatetherapeutics.com (FATE): Rasio Utang marang Ekuitas saka 04.07.2022 nganti 30.10.2026

Rincian metrik lan analitis perusahaan Fate Pharma (FATE)

- rega saham lan konsensus proyeksi valuasi:
Rega saham Fate Therapeutics|FATE - Target konsensus
- rincian kapitalisasi pasar:
Kapitalisasi pasar Fate Therapeutics|FATE - Nilai Perusahaan
- indikator kapitalisasi buku:
Aset Bersih saben Siji Saham Fate Therapeutics|FATE - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku fatetherapeutics.com|FATE - Gunggung Aset Perusahaan
- rincian utang lan likuiditas:
Total Utang marang Modal Fate Therapeutics, Inc.|FATE - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Fate Therapeutics, Inc.|FATE - Kewajiban utang agregat|Utang marang nilai buku Fate Therapeutics|FATE - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Fate Therapeutics|Indikator likuiditas cepet fatetherapeutics.com
- data bathi resik lan rasio valuasi:
FATE - Bathi resik
Pambiji fundamental perusahaan:Fate Therapeutics
Produk dadi Fate Therapeutics, Inc.

The robotization of cell synthesis at Fate Therapeutics, Inc. (FATE) requires capital-intensive investments in automation and sterile bioreactors. These expenditures are reflected in the liability structure, where all obligations are aggregated and compared against net assets. This metric measures the business development's reliance on borrowed funds relative to equity. By analyzing the company's leverage through the debt-to-equity ratio, an investor assesses the issuer's financial stability. This chart allows for the differentiation of market noise from the company's actual solvency.

Analisis pesaing Fate Therapeutics, Inc.

ONC (BeiGene) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas Halozyme Therapeutics, Inc. (HALO)|Total Utang marang Modal RVMD|Total Utang marang Modal Ascentage Pharma Corp (AAPG)|Utang marang Ekuitas CG Oncology, Inc. CGON|URGN: Rasio Utang marang Ekuitas|Bicara Therapeutics - Total Utang marang Modal|Personalis Inc (PSNL) - Rasio Total Utang marang Ekuitas|ERAS: Total Utang marang Modal|Utang marang Modal Delcath Corp (DCTH)|Utang marang Ekuitas Y-mAbs Therapeutics|AURA: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas CADL (Candel Therapeutics)|ARAY (Accuray Inc) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal SLS (SELLAS Life Sciences Group)|ACTU - Rasio Total Utang marang Ekuitas|CTOR: Rasio Total Utang marang Ekuitas|HURA - Total Utang marang Modal|Protara Therapeutics, Inc. (TARA) - Utang marang Ekuitas|Aadi Bioscience - Rasio Kabeh Utang marang Dana Pribadi|TCRX (TScan Therapeutics Inc) - Total Utang marang Modal|Utang marang Modal Champions Oncology Corp CSBR|Total Utang marang Modal XBIT|CVM: Utang Agregat marang Ekuitas|Total Utang marang Modal OSTX (OS Therapies)|Total Utang marang Modal radiopharmtheranostics.com RADX|ARTV: Rasio Total Utang marang Ekuitas|Adlai Nortye Ltd. - Utang Agregat marang Modal|VERU: Total Utang marang Modal|Utang marang Modal tempesttx.com (TPST)|Rasio Total Utang marang Ekuitas XLO|RENB: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas MURA (Mural Oncology plc)|Utang Agregat marang Modal KAPA|Total Utang marang Modal OKUR (OnKure Therapeutics)|Rasio Kabeh Utang marang Dana Pribadi GDTC|Curis Corp - Total Utang marang Modal|Utang marang Modal Apollomics, Inc.|Tharimmune Corp (THAR) - Utang marang Ekuitas|Advanced Biomed - Rasio Kabeh Utang marang Dana Pribadi|GNPX (Genprex, Inc.) - Total Utang marang Modal|Total Utang marang Modal Calidi Bio|Utang marang Ekuitas Sunshine Biopharma, Inc. (SBFM)|XBIO: Utang Agregat marang Ekuitas|Total Utang marang Modal SLRX (Salarius)|Kitov Pharma (PPBT) - Utang marang Modal|AONC: Rasio Total Utang marang Ekuitas|BGNE - Total Utang marang Modal|CKPT (Checkpoint Therapeutics, Inc.) - Rasio Total Utang marang Ekuitas|ELEV: Utang Agregat marang Modal|ICAD (iCAD Inc.) - Total Utang marang Modal|Ikena (IKNA) - Koefisien Total Utang marang Modal|Total Utang marang Modal NTBL|Rasio Total Utang marang Ekuitas viracta.com VIRX|Utang marang Ekuitas MorphoSys MOR|Koefisien Total Utang marang Modal NAYA Biosciences Inc (NAYA)|AAPGV: Rasio Total Utang marang Ekuitas